CRYO Cryo-Save

 

TIDMCRYO 
 
RNS Number : 2651A 
Cryo-Save Group NV 
05 October 2009 
 

This announcement and the information contained herein is not for release, 
publication or distribution, directly or indirectly, in or into the United 
States, Australia, Canada, Japan, South Africa or any jurisdiction in which the 
same would be unlawful. This announcement is not an offer of securities in the 
United States, Canada, South Africa, Australia, Japan or any other jurisdiction. 
 
 
 
 
 
 
5 October 2009 
 
 
Cryo-Save Group NV 
 
 
EGM Resolutions and share consolidation 
 
 
Cryo-Save Group N.V. (AIM: CRYO, "Cryo-Save" or "the Group"), Europe's leading 
stem cell bank, announces that all resolutions at today's EGM were passed. 
 
 
The Group is on course to secure its additional listing on Euronext Amsterdam by 
mid October to complement the Group's shares being traded on AIM in London. 
Cryo-Save will not be issuing any new shares or raising new funds. 
 
 
Following the adoption of the first amendment of the Articles of Association at 
today's EGM, the 5:1 consolidation and redenomination of the shares is expected 
to take place following the close of trading of the shares on AIM on 7 October 
2009. As a consequence of the share consolidation, for every five shares with a 
nominal value of 2 euro cents held by a shareholder immediately prior to the 
close of trading on 7 October 2009, a shareholder will hold one share with a 
nominal value of 10 euro cents. 
 
 
Immediately after the share consolidation, the Group will have a total number of 
9,639,191 issued shares, each with a nominal value of 10 euro cents. 
 
 
 
 
The information contained herein is not for publication or distribution, 
directly or indirectly, in or into the United States of America (including its 
territories and possessions, any State of the United States and the District of 
Columbia). These materials do not contain or constitute an offer for sale or the 
solicitation of an offer to purchase securities in the United States or any 
other jurisdiction. The securities mentioned herein have not been and will not 
be registered under the U.S. Securities Act of 1933, as amended (the "Securities 
Act"), and may not be offered or sold in the United States absent registration 
under the Securities Act or an available exemption from, or transaction not 
subject to, the registration requirements of the Securities Act. 
This announcement is not a prospectus. In connection with the admission of the 
shares in the capital of the Company to trading on Euronext Amsterdam by NYSE 
Euronext, a prospectus shall in due course be made generally available. Copies 
of the Prospectus will, following publication, be available at no cost through 
the website of the Company (www.cryo-savegroup.com) and the website of Euronext 
Amsterdam (Dutch residents only) and by sending a request in writing to the 
Company at its business address: IJsselkade 8, 7201 HB Zutphen, the Netherlands. 
 
 
+------------------------------------+---------------------------------+ 
| For further details:               |                                 | 
+------------------------------------+---------------------------------+ 
|                                    |                                 | 
+------------------------------------+---------------------------------+ 
| Cryo-Save Group                    | + 31 (0)575 548998              | 
+------------------------------------+---------------------------------+ 
| Marc Waeterschoot, Chief Executive |                                 | 
|                                    |                                 | 
+------------------------------------+---------------------------------+ 
| Arnoud van Tulder, Chief Financial |                                 | 
| Officer                            |                                 | 
+------------------------------------+---------------------------------+ 
|                                    |                                 | 
+------------------------------------+---------------------------------+ 
| Daniel Stewart & Company plc       | + 44 (0) 20 7776 6550           | 
+------------------------------------+---------------------------------+ 
| Simon Leathers                     |                                 | 
+------------------------------------+---------------------------------+ 
|                                    |                                 | 
+------------------------------------+---------------------------------+ 
| College Hill                       | + 44 (0) 20 7457 2020           | 
+------------------------------------+---------------------------------+ 
| Adrian Duffield/Rozi Morris        |                                 | 
+------------------------------------+---------------------------------+ 
 
 
 
 
About Cryo-Save 
With more than 115,000 samples saved, Cryo-Save is the leading stem cell bank in 
Europe and one of the fastest growing in the world. Driven by its international 
business strategy, Cryo-Save is now represented in 38 countries on three 
continents and has state-of-the-art processing facilities in Belgium, Germany, 
Dubai, India and France (under construction). 
Cryo-Save sets the highest quality standards in stem cell storage, as it aims to 
make an important contribution to conquer possible life-threatening diseases in 
the future. As a service to the public, Cryo-Save offers a Cost-free Family 
Donation Programme, free of charge, to families wishing to store their newborn's 
umbilical cord blood stem cells for a family member diagnosed with a 
life-threatening disease treatable by stem cells. The company is committed to 
further improve stem cell cryopreservation techniques, by participating in 
European Commission funded projects, in Universities and Hospitals. 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 REGUVSVRKBRRRAA 
 

Cryo-Save (LSE:CRYO)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024

Cryo-Save (LSE:CRYO)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024